Skip to main content

Table 1 Patients’ Characteristics

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Characteristics Number %
Age (years)
 Median (IQR) 61 (18)  
60 24 49.0
  > 60 25 51.0
Gender
 Male 22 44.9
 Female 27 55.1
Performance status
 0 29 59.2
 1 13 26.5
 2 6 12.2
 3 1 2.0
Location of primary site
 Extremities 18 36.7
 Head and neck 9 18.4
 Trunk 16 32.7
 Unknown 6 12.2
Type
 Acral melanoma 15 30.6
 Non-acral cutaneous melanoma 5 10.2
 Mucosal melanoma 16 32.7
 Others 7 14.3
 Unknown 6 12.2
Stage
 3 6 12.2
 4, M1a 5 10.2
 4, M1b 8 16.3
 4, M1c 30 61.2
BRAF gene mutation
 No 34 69.4
 Yes 9 18.4
 Unknown 6 12.2
Treatment regimen
 Nivolumab 33 67.3
 Pembrolizumab 16 32.7
Immunotherapy therapy
 First-line 31 63.3
 Second-or later-line 18 36.7
Response
 CR 2 4.1
 PR 3 6.1
 SD 9 18.4
 PD 29 59.2
 N/A 6 12.2
  1. IQR interquartile range, CR complete response, PR partial response, SD stable disease, PD progressive disease, N/A not assessed